News | Radiation Therapy | February 09, 2016

UCLA study finds HPV-negative cancer cells are more easily converted into head and neck cancer stem cells than those that are HPV-positive

radiation therapy, head and neck cancers, HPV status, UCLA study

February 9, 2016 — Head and neck cancers that test positive for the herpes papilloma virus (HPV) are known to respond more favorably to radiation therapy than those that test HPV-negative, but an explanation for these differences has remained elusive.

Now, UCLA scientists have shown for the first time that radiation treatment transforms cancer cells into head and neck cancer stem cells — which are known to be resistant to radiation therapy — more effectively when the cancer tests negative for HPV. These findings shed light on why some head and neck cancers fair much worse after radiation therapy despite optimum treatment regimens.

Led by UCLA Jonsson Comprehensive Cancer Center members Erina Vlashi, M.D., and Frank Pajonk, M.D., the study showed the non-stem cancer cells that survived radiation therapy had the ability to convert into cancer stem cells, which have shown to be more resistant to radiation treatment. The process, called “radiation-induced conversion,” happened at a higher frequency in HPV-negative head and neck cancers, providing a clinically relevant explanation for the differences in response to radiation therapy.

The team reviewed 162 head and neck squamous carcinomas (HNSCCs) patients over a two-year period, and confirmed that their outcomes were correlated with their HPV status.

The study was built upon Vlashi and Pajonk’s previous research in breast cancer, which showed that therapy-resistant cancer cells are more prone to therapy-induced conversion depending on the aggressiveness of the type of breast cancer.

While radiation therapy may have some unwanted consequences, it remains an indispensable treatment for people with the disease. Further studies are currently underway to identify drugs that can interfere with radiation-induced conversion, said Vlashi.

The scientists hope this research will lead to a new type of combination treatment to improve the response of head and neck tumor cells to radiation therapy.

The study is available online in the International Journal of Radiation Oncology, Biology and Physics.

For more information: www.redjournal.org


Related Content

News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
Subscribe Now